ArticleAmerican journal of respiratory and critical care medicine2024
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.
Abstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Healthy diet and slower biological aging as protective factors against microvascular complications in type 2 diabetes.GeroScience · 2026Article
- Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.Research square · 2026Article
- Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- Exploratory Study of Prognostic Plasma Biomarkers in Patients with Pulmonary Arterial Hypertension.The American journal of pathology · 2025Article
- Mechanisms and markers of lung ageing in health and disease.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- From Birth to Breathless: The Confluence of Early-Life Tobacco Exposure and Genetics in Idiopathic Pulmonary Fibrosis.Annals of the American Thoracic Society · 2025Article
- Associations of lung function impairment and biological aging with mortality and cardiovascular disease incidence: findings from UK biobank participants.Frontiers in public health · 2025Article
- Unveiling Biological Age: A New Frontier in Predicting Outcomes in Chronic Lung Disease.American journal of respiratory and critical care medicine · 2024Article
Corrections and comments
- Commented on by
Authors and funding
20 authors.
Janelle Vu PugashettiDivision of Pulmonary and Critical Care Medicine.ORCID 0000-0002-8889-2757
John S KimDivision of Pulmonary and Critical Care Medicine and.
Swaraj BoseDepartment of Biostatistics, and.
Ayodeji AdegunsoyeSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Angela L LinderholmDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, Sacramento, California.
Ching-Hsien ChenDivision of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, Sacramento, California.ORCID 0000-0002-4211-9988
Mary E StrekSection of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine.
Susan MurrayDepartment of Biostatistics, and.
Chad A NewtonPulmonary Fibrosis Foundation, Chicago, Illinois.ORCID 0000-0001-5256-9029
Shehabaldin AlqalyoobiDivision of Pulmonary and Critical Care, East Carolina University, Greenville, North Carolina.ORCID 0000-0001-5602-2725
Shwu-Fan MaDivision of Pulmonary and Critical Care Medicine and.ORCID 0000-0002-3058-9480
Josyf C MychaleckyjSchool of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
Russell P BowlerDivision of Pulmonary Medicine, National Jewish Health, Denver, Colorado.ORCID 0000-0003-4651-363X
MeiLan K HanDivision of Pulmonary and Critical Care Medicine.
Jeffrey L CurtisDivision of Pulmonary and Critical Care Medicine.ORCID 0000-0001-5191-4847
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, Weill Cornell Medical Center, New York, New York.
Jennifer A SmithDepartment of Epidemiology, University of Michigan, Ann Arbor, Michigan.
Imre NothDivision of Pulmonary and Critical Care Medicine and.
Justin M OldhamDivision of Pulmonary and Critical Care Medicine.ORCID 0000-0003-4957-8869
Funding
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9MPULMONARY CELLULAR AND MOLECULAR BIOLOGY TRAININGT32HL007749 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Pickett Dickson · 1993 to 2026
$19.9MUnderstanding the Origins of Early COPDR01HL144718 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CURTIS, JEFFREY LOUIS, HAN, MEILAN K · 2020 to 2024
$11.3MSPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2MArchitectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1MProteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7MPrognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977kMolecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891kRole of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858kImproving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810kNHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23HL146942NHLBI NIH HHS K23 HL148498NHLBI NIH HHS K23HL148498NHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23HL150301NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R01 HL144718NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R01HL169166NHLBI NIH HHS RO1HL130796NHLBI NIH HHS T32 HL007749NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NHLBI NIH HHS UG3 HL145266NHLBI NIH HHS UG3HL145266
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgingIdiopathic Pulmonary FibrosisAgedAged, 80 and overBlood ProteinsCohort StudiesFemaleHumansMaleMediation AnalysisMiddle AgedProteomicsSurvival AnalysisBlood Proteinsagecausal mediationidiopathic pulmonary fibrosisproteomics
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.